Eisai Receives U.S. FDA Complete Reponses Letter For Aricept Transdermal Patch
This article was originally published in PharmAsia News
Executive Summary
Eisai announced that U.S. FDA issued a complete response letter for Aricept (donepezil) patch for Alzheimer's disease